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A B S T R A C T

Introduction: Accurate early diagnosis of Parkinson's disease is hampered by its long prodromal period and the variable
manifestations of its motor symptoms. While olfactory dysfunction can occur before motor-symptom onset and serve
as a non-disease-speciﬁc diagnostic aid, its underlying causes are incompletely understood.
Methods: Correlation analyses, univariate density estimates, ANOVA and regression evaluated relationships between
scores on the Montreal Cognitive Assessment and Hopkins Verbal Learning Test and those on the University of Pennsylvania Smell Identiﬁcation Test in 1280 Parkinson's Progression Markers Initiative subjects placed into ﬁve diagnostic categories. Structural equation modeling identiﬁed cognitive measures having signiﬁcant indirect effects on
olfactory-function-test scores.
Results: Global cognition, verbal learning and memory, attention, delayed-recall, and visuospatial/executive function
scores show weak-to-moderate, signiﬁcant associations with olfactory-function-test scores. Associations are stronger in
symptomatic than asymptomatic subjects having mutations in LRRK2, GBA or SNCA. Score distributions are nonuniform
across diagnostic categories. Linear regression found that all cognitive measures except attention predicted olfactoryfunction-test scores. Three structural equation models assessing indirect effects of verbal learning/memory with either
global cognition, visuospatial/executive function, or delayed-recall had a good statistical ﬁt to the data. Only verbal learning/memory scores signiﬁcantly help explain olfactory-function-test scores in all symptomatic diagnostic categories
(−0.56 < b < −0.23, 0.001 < P < .005). Visuospatial/executive-function test scores help explain olfactory-functiontest scores in both genetic Parkinson's disease diagnostic categories (−0.25 < b < −0.17, 0.032 < P < .033).
Conclusion: Impaired verbal learning/memory and visuospatial/executive function contributes to lower performance on
olfactory function tests in Parkinson's disease. As both of these domains impact decision-making, decision-making in
turn may impact olfactory assessment in Parkinson's disease.

1. Introduction
Accurate diagnosis of Parkinson's disease (PD) is complicated by the variable manifestations of motor and non-motor symptoms. Assessment of olfactory dysfunction, an early non-motor symptom present in up to 90% of PD
patients [1], may serve as an ancillary diagnostic criterion [2–5]. However,
it is not speciﬁc to PD: it is found in other neurodegenerative diseases and
healthy aging [6,7]. It is therefore important to understand how its onset
and progression relates to PD motor and non-motor manifestations.
Interpreting olfactory stimuli requires primary sensory detection along
with multiple levels of associative sensory-signal processing. Clinically
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used tests of olfactory function implicitly measure multiple domains, as
tests of odor detection, discrimination, and identiﬁcation require information processing within the olfactory bulb and higher-order associative centers. They may be sensitive to speciﬁc types of cognitive impairment, such
as memory decline that affects odor-memory retention or the associative
processing of an odor memory.
If a subtle cognitive deﬁcit contributes to lower scores on olfactory function tests, then subjects retaining some olfactory function might obtain similar scores but misidentify different odors upon retesting. Such odoridentiﬁcation irreproducibility was observed but could not be explained by
global-cognition test scores [8]. This suggests that routinely used clinical
measures of cognitive performance in PD may have limited sensitivity to detect the cognitive deﬁcits that impact performance on olfactory-function tests.
Here, we identify speciﬁc cognitive deﬁcits that help explain lower
scores on tests of olfactory function in PD and quantify the magnitude of
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(RBD)), as this is a potentially informative comparison group due to a high
prevalence of hyposmia (71% have UPSIT < 21).

their indirect effects by developing structural equation models (SEM) using
data from the Parkinson's Progression Marker Initiative (PPMI). This report
extends previous research demonstrating that memory is strongly related to
olfaction [9–11] and builds on previously established correlative associations and predictive relationships between deﬁcits in olfaction and verbal
learning/memory in PD [12,13]. In addition to quantifying the contributions of verbal learning/memory, we also assess visuospatial/executive
function, which is frequently impaired in PD [14], attention, and delayedrecall. Quantifying how poorer performance on tests of these cognitive
measures contributes to lower scores on olfactory function tests provides insight into how and why olfactory test scores decline in some PD patients,
and how potentially subtle alterations in cognition in PD impact seemingly
unrelated clinical assessments.

2.3. ANOVA and SEM
Since MoCA, Visu-Exec, and UPSIT scores were somewhat skewed, we
used the robust maximum likelihood parameter estimator [22]. ANOVA
testing for homogeneity of variance revealed some violation (1.3:1 male:female). ANOVA t and F statistics are sufﬁciently robust to handle this violation [23].
We used SEM (Mplus version 7.11), which incorporates both factor and
regression analyses [24,25], to evaluate models in which cognitive processes are hypothesized to have indirect effects on (i.e., help explain) the relationship between olfactory dysfunction and a PPMI-diagnostic category,
relative to healthy controls. Signiﬁcant models with a good ﬁt to the data
had model chi-square (χ2) α ≥ 0.05, comparative ﬁt index (CFI) ≥ 0.93
(1 = perfect ﬁt), root mean square error of approximation (RMSEA)
≤0.08, and standard root mean square residual (SRMR) ≤0.08 [24]. We
used such models to infer whether a cognitive measure has an indirect effect on, or a signiﬁcant role in explaining, the relationship between UPSIT
scores and a diagnostic category, and to infer its magnitude.

2. Subjects and methods
2.1. Assessments
Data used in the preparation of this article were obtained from the PPMI
database (www.ppmi-info.org/data) in September 2018. For study information, visit www.ppmi-info.org. We analyzed scores on the University of
Pennsylvania Smell Identiﬁcation Test (UPSIT), a forced-choice test of
odor identiﬁcation [15], the Hopkins Verbal Learning Test (HVLT), an assessment of verbal learning and memory that is a signiﬁcant predictor of dementia [16,17], and the Montreal Cognitive Assessment (MoCA), which
evaluates visuospatial/executive function, attention/concentration, naming, language, immediate and delayed-recall, calculations and orientation,
and accurately assesses cognitive impairment in PD [14,18]. We used
only the three free-recall memory trials of the HVLT, since they and the
UPSIT similarly rely on the processes of short-term/working memory, semantic and/or episodic memory, and association. They may be used in
the UPSIT to retain an odor memory while selecting among words for an olfactory cue, while they are used in the free-recall trials of the HVLT to recall
auditory cues (words read aloud). We also assessed MoCA subscores for visuospatial/executive function (Visu-Exec), attention/concentration (Attention), and delayed-recall (Delayed-Recall), as these cognitive domains are
commonly and potentially differentially affected in PD and are also used
in olfactory coding and memory [19–21]. These subscores have utility in
understanding cognitive phenotypes of PD [14], akin to using Uniﬁed
Parkinson's Disease Rating Scale subscores in assessing motor subtypes.
Since the UPSIT, HVLT, and MoCA were administered together only at
study baseline, we analyzed only baseline assessments.

3. Results
3.1. Descriptive statistics and correlations
Table 1 presents descriptive statistics for study subjects and Pearson
zero-order correlations between study variables. The latter reveal weakto-moderate, signiﬁcant positive associations between scores on tests of olfaction and cognition: if a subject had lower scores on one test, they tended
to score lower on the others as well. In contrast, scores showed weak negative correlations with age. To understand whether positive correlations between scores reﬂect similar score distributions in all diagnostic categories,
we compared their distributions and univariate density estimates [26] between diagnostic categories. Score distributions are nonuniform between
diagnostic categories (Fig. 1, Supplemental Figs. 1–2). Speciﬁcally, the distributions of UPSIT, HVLT, and MoCA scores in healthy controls are clearly
distinct from those in other diagnostic categories. Therefore, we asked how
the study measures were correlated for each of the diagnostic categories
compared to healthy controls (Supplemental Table 1). This conﬁrmed previously demonstrated positive associations found in idiopathic PD between
scores on the USPIT and tests of verbal learning/memory [12,13], and discovered signiﬁcant associations between scores on the UPSIT, MoCA,
HVLT, Visu-Exec and Delayed-Recall in each symptomatic diagnostic category. Strikingly, these associations are stronger in symptomatic than
asymptomatic subjects with genetic-PD. Taken together, these analyses suggest that the underlying neurodegenerative process(es) affect
(s) interactions between the tested cognitive domains.

2.2. Subjects
We analyzed data from ﬁve well-deﬁned PPMI-assigned diagnostic categories (https://www.ppmi-info.org/study-design/). The main diagnostic
categories were sporadic PD (≥2 of resting tremor, bradykinesia, or rigidity, with resting tremor or bradykinesia required, or either asymmetric resting tremor or asymmetric bradykinesia; PD diagnosis ≤2 years; Hoehn and
Yahr (H&Y) I-II; scan-conﬁrmed dopaminergic deﬁcit; ≥30 years at diagnosis; no dopaminergic medications ≥6 months after baseline assessment)
and healthy controls (≥30 years, no active neurological disorder or ﬁrstdegree relative with idiopathic PD, MoCA ≥26, scan-negative for dopaminergic deﬁcit). We included two diagnostic categories of subjects who are at
increased genetic-risk of developing PD, symptomatic-genetic-PD (motor
symptoms in sporadic-PD diagnostic category, PD diagnosis ≤7 years,
H&Y I-III, ≥18 years, and a LRRK2, GBA, or SNCA mutation) and
asymptomatic-genetic-PD (no PD diagnosis at baseline, ≥45 years, mutation or ﬁrst-degree relative with mutation in either LRRK2 or GBA, or
≥ 30 years, mutation or ﬁrst-degree relative with mutation in SNCA), as
the disease phenotypes are similar to sporadic PD and their inclusion allows
for comparisons in individuals having a known disease cause before and
after motor-symptom onset. We included the possible-prodromal-PD diagnostic category (≥60 years, hyposmia and/or REM-behavior sleep disorder

3.2. ANOVA
Separate, univariate ANOVAs investigated whether mean UPSIT, HVLT,
MoCA, Visu-Exec, Delayed-Recall and Attention scores differ between the
ﬁve diagnostic categories, holding age and sex constant as covariates.
There are signiﬁcant differences between the effects of diagnostic categories on scores on the UPSIT (F6,1273 = 138.63, P = 3.19 × 10−135, η2 =
0.395), HVLT (F6,1273 = 31.68, P = 1.20 × 10−35, η2 = 0.126), and
MoCA (F6,1269 = 26.23, P = 1.56 × 10−29, η2 = 0.011), and on MoCA
subscores for Visu-Exec (F6,1273 = 9.78, P = 1.47 × 10−10, η2 = 0.044),
Delayed-Recall (F6,1273 = 23.21, P = 5.54 × 10−13, η2 = 0.049) and Attention (F6,1273 = 9.245, P = 6.18 × 10−10, η2 = 0.037).
Bonferroni post-hoc analyses evaluated signiﬁcant differences in mean
scores between pairs of diagnostic categories (Table 2). Healthy controls
had higher means on all tests than subjects in symptomatic diagnostic categories, and higher means on all tests except the HVLT than
asymptomatic-genetic-PD subjects. In turn, asymptomatic-genetic-PD
2
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Fig. 1. Graphical comparison of univariate density estimates for study variables. (A) UPSIT score. (B) HVLT score. (C) MoCA score. (D) Visuospatial/Executive Subscore.
(E) Delayed-Recall Subscore. (F) Attention Subscore. Table cells within each panel are shaded to indicate the P value (white: P ≥ .05, gray: 0.05 > P ≥ .001, black: P <
.001) obtained from pairwise nonparametric bootstrap tests of equal densities using 1000 permutations [26]. PPMI-deﬁned diagnostic categories: HC = healthy controls;
GENUN = individuals with asymptomatic genetic (LRRK2, SNCA, or GBA) PD; GENPD = individuals with symptomatic genetic PD; SPD = individuals with sporadic PD
at baseline; PROD (possible prodromal PD) = individuals diagnosed with hyposmia and/or RBD.

UPSIT scores by regressing UPSIT scores on the PPMI diagnostic categories.
Mirroring the ANOVA results, UPSIT scores in the sporadic-PD,
asymptomatic-genetic-PD, symptomatic-genetic-PD and possible-prodromalPD diagnostic categories were signiﬁcantly different from those in the
healthy-control category. Speciﬁcally, healthy controls had UPSIT scores closest to asymptomatic-genetic-PD (b = −1.05, Standard Error (SE) = 0.44, z =
−2.38, P = .017) while symptomatic individuals showed larger differences
[symptomatic-genetic-PD (b = −12.56, SE = 0.69, z = −18.21, P <
.001), sporadic-PD (b = −10.62, SE = 0.52, z = −20.44, P < .001) and
possible-prodromal-PD (b = −16.84, SE = 0.90, z = −18.69, P < .001)].
Thus, subjects in all symptomatic diagnostic categories had poorer olfactory
function than healthy controls. Overall, the ﬁve diagnostic categories explained 36.6% of the variance in UPSIT scores.
We also used regression analysis to verify that the potentially mediating
variables (MoCA and HVLT) are predictive of UPSIT scores after controlling
for associations between HVLT and MoCA scores. MoCA scores (b = 0.07,
SE = 0.03, z = 2.31, P = .021) and HVLT scores (b = 0.25, SE = 0.03, z
= 8.46, P < .001) signiﬁcantly predicted UPSIT scores and together explained 8.3% of the variance in UPSIT scores. In separate, simple

subjects had means higher than those in all symptomatic diagnostic categories, except for having lower Delayed-Recall means than sporadic-PD subjects. Symptomatic-genetic-PD subjects, compared to sporadic-PD
subjects, had lower UPSIT, MoCA and Attention means, higher VisuExec
means, and similar HVLT and Delayed-Recall means. Possible-prodromalPD subjects had means similar to or lower than those in all other diagnostic
categories, except for having higher Visu-Exec means than sporadic-PD subjects. PPMI-inclusion criteria may contribute to differences between some
diagnostic categories: inclusion criteria for healthy controls speciﬁed
MoCA ≥26 and they had greater MoCA means than all other diagnostic categories; symptomatic-genetic-PD subjects with disease duration ≤7 years
had lower UPSIT, MoCA, and Attention means than sporadic-PD subjects
with disease duration ≤2 years; possible-prodromal-PD subjects had RBD
and/or hyposmia.
3.3. The indirect effects of cognitive processes
Before building SEM models to evaluate the indirect effects of cognitive
processes, we conﬁrmed that PPMI diagnostic categories are predictive of
3
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Table 1
Descriptive statistics of study subjects and correlations between study variables.
Study variable

Mean ± standard deviation

Pearson correlation coefﬁcient and P-valueb

PPMI diagnostic category

Study variable

Healthy
controls
n = 198
F = 71
UPSIT (40)a

Asymptomatic
genetic Parkinson's
disease
n = 310
F = 187

Symptomatic
genetic Parkinson's
disease
n = 220
F = 113

Sporadic
Parkinson's
disease
n = 491
F = 169

Possible prodromal UPSIT
Parkinson's disease n =
1280
n = 61
F = 13

34.0 ±
4.8
26.0 ±
4.5

33.0 ± 4.9

21.5 ± 8.9

23.4 ± 8.7

17.2 ± 6.6

26.5 ± 5.2

24.0 ± 5.6

24.4 ± 4.9

22.0 ± 5.3

MoCA (30)a

28.2 ±
1.1

26.7 ± 2.3

25.9 ± 3.5

27.1 ± 2.3

26.2 ± 3.6

Visu-Exec (5)a

4.66 ±
0.59

4.35 ± 0.88

4.22 ± 0.99

4.49 ± 0.80

4.03 ± 1.21

Delayed-Recall
(5)a

3.88 ±
0.98

3.04 ± 1.57

3.22 ± 1.48

3.35 ± 1.41

3.31 ± 1.43

Attention (6)a

5.89 ±
0.32

5.72 ± 0.56

5.49 ± 0.90

5.76 ± 0.59

5.39 ± 1.37

Age

67.4 ±
11.0

63.9 ± 7.4

64.4 ± 10.2

67.8 ± 9.8

72.8 ± 6.1

HVLT (30)a

HVLT
n=
1280

MoCA
n=
1276

Visu-Exec Delayed
recall
n=
n=
1280
1279

Attention Age
n=
n=
1280
1280

–
0.281
–
1.2 ×
−24
10
0.182
0.449
–
6.2 ×
1.9 ×
10−11
10−64
0.132
0.195
0.353
2.2 ×
1.9 ×
7.8 ×
−6
−12
10
10
10−39
0.088
0.243
0.468
1.6 ×
1.1 ×
2.5 ×
10−3
10−18
10−70
0.104
0.171
0.395
2.1 ×
7.5 ×
5.5 ×
10−4
10−10
10−49
−0.190 −0.258 −0.160
7.4 ×
6.4 ×
8.3 ×
10−12
10−21
10−9

–

0.185
2.8 ×
10−11
0.323
2.0 ×
10−32
−0.090
1.3 ×
10−3

–

0.227
2.1 ×
10−16
−0.088
1.6 ×
10−3

–

0.011
6.9 ×
10−1

–

a

Maximum score or subscore on assessment.
Correlations calculated with missing-value cases excluded pairwise, bold indicates signiﬁcance at the 0.01 level (two-tailed). UPSIT: University of Pennsylvania Smell
Identiﬁcation Test. HVLT: Hopkins Verbal Learning Test. MoCA: Montreal Cognitive Assessment Test. Visu-Exec: MoCA subscore for visuospatial and executive function. Delayed-Recall: MoCA subscore for delayed recall. PPMI-deﬁned diagnostic groups: Asymptomatic-genetic-Parkinson's-disease subjects have a mutation, or are a ﬁrst-degree
relative of an individual having a mutation, in LRRK2, SNCA, or GBA; Symptomatic-genetic-Parkinson's-disease subjects have a mutation in LRRK2, SNCA, or GBA; Possible-prodromal-Parkinson's-disease subjects have REM-behavior sleep disorder and/or hyposmia.
b

were regressed against the asymptomatic-genetic-PD, symptomatic-geneticPD, sporadic-PD and possible-prodromal-PD diagnostic categories, comparing them to healthy controls with age and sex as covariates, and using
MoCA scores as a mediating variable. The resulting regression model was signiﬁcant (F7,1268 = 120.6, P = 1 × 10−135, R2 = 0.4) and explained 40% of
the variability in UPSIT scores and 11% of the variability in MoCA scores.
Age, sex, the non-healthy-control diagnostic categories, and MoCA scores
were signiﬁcant predictors of UPSIT scores (Supplemental Table 2). MoCA
scores have signiﬁcant indirect effects on the relationship between UPSIT
scores and the diagnostic categories of asymptomatic-genetic-PD (b =
−0.45, P = .010), symptomatic-genetic-PD (b = −0.63, P = .012),
sporadic-PD (b = −0.27, P = .012), and possible-prodromal-PD (b =
−0.42, P = .013). Thus, MoCA scores do have signiﬁcant indirect effects,
but they are no longer signiﬁcant when HVLT scores also are included in
the model. Therefore, the HVLT more effectively captures the indirect effects
of cognition on the relationship between a diagnostic category and UPSIT
than does the MoCA.
To determine whether MoCA subscores for Visu-Exec, Attention or
Delayed-Recall, by themselves, have signiﬁcant indirect effects, we replaced total MoCA scores with these subscores and tested them using regression analyses. Only the Visu-Exec and Delayed-Recall subscores were
signiﬁcant predictors of UPSIT scores. We then built SEM models to evaluate the indirect effects of (1) Visu-Exec, (2) Delayed-Recall (3) Visu-Exec
and HVLT and (4) Delayed-Recall and HVLT.
Visu-Exec had signiﬁcant indirect effects on the relationship between
UPSIT and the diagnostic categories of asymptomatic-genetic-PD (b =
−0.22, P = .008), symptomatic-genetic-PD (b = −0.32, P = .007),
sporadic-PD (b = −0.12, P = .030), and possible-prodromal-PD (b =
−0.45, P = .017). An SEM model with Visu-Exec and HVLT scores had a
good ﬁt to the data (χ2(1) = 0.95, P = .329, CFI = 1.00, RMSEA = 0.00,
SRMR = 0.002) and explained 40.9% of the variability in UPSIT scores,
12.9% of the variability in HVLT scores and 4.3% of the variability in
Visu-Exec subscores (Fig. 2B). It revealed 1) signiﬁcant indirect associations

regressions of UPSIT on MoCA and UPSIT on HVLT, the MoCA was a significant predictor of the UPSIT (b = 0.18, SE = 0.03, z = 6.54, P < .001), as
was the HVLT (b = 0.28, SE = 0.03, z = 10.88, P < .001). Though each
individually was a signiﬁcant predictor of the UPSIT, when both were considered as joint predictors, the MoCA lost more of its predictive magnitude
and strength than did the HVLT.
Since the diagnostic categories, HVLT scores, and MoCA scores were all
predictive of UPSIT scores, we built an SEM model to assess whether HVLT
and MoCA scores have indirect effects on the relationship between the diagnostic categories and UPSIT scores. This model compared each of the PDrelated diagnostic categories to healthy controls, included UPSIT scores
regressed onto all diagnostic categories, the indirect effects of HVLT and
MoCA scores on these relationships, and the effects of the age and sex as covariates, since olfactory function declines during healthy aging and differs
between sexes. The relationship between HVLT scores and the
asymptomatic-genetic-PD diagnostic category was not signiﬁcant, so this
association was set to zero to give the model one degree of freedom. That
had no effect on other model relationships. The resulting model (Fig. 2A)
was a good ﬁt to the data (χ2(1) = 0.95, P = .329, CFI = 1.00, RMSEA
= 0.00, SRMR = 0.004) and explained 40.7% of the variability in
UPSIT, 12.9% in HVLT and 10.7% in MoCA scores. Thus, 40.7% of the variability in UPSIT scores is attributable to age, sex, diagnostic category,
HVLT scores and MoCA scores.
In this model, MoCA scores do not have signiﬁcant indirect effects on
the relationships between each of the four non-healthy-control diagnostic
categories and UPSIT scores. In contrast, HVLT scores have signiﬁcant indirect effects on the relationships between all symptomatic diagnostic categories and UPSIT scores. Importantly, this model indicates that HVLT scores
provide a better explanation for UPSIT scores in symptomatic diagnostic
categories than do MoCA scores.
Given our and others' [27,28] results documenting the relationship between MoCA scores and olfactory function, we assessed the magnitude of
the indirect effects of MoCA scores without HVLT scores. UPSIT scores
4
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Table 2
ANOVA Bonferroni post-hoc analysis.
Healthy
controls
A. UPSIT
Healthy controls
Asymptomatic genetic Parkinson's disease

Symptomatic genetic Parkinson's disease

Sporadic Parkinson's disease

Prodromal

B. HVLT
Healthy controls
Asymptomatic genetic Parkinson's disease

Symptomatic genetic Parkinson's disease

Sporadic Parkinson's disease

Prodromal

C. MoCA.
Healthy controls
Asymptomatic genetic Parkinson's disease

Symptomatic genetic Parkinson's disease

Sporadic Parkinson's disease

Prodromal

–
−1.06 ± 0.67
0.82 to −2.94
1.000
−12.56* ± 0.72
−14.58 to
−10.53
<0.001
−10.56* ± 0.62
−12.36 to −8.89
<0.001
−16.84* ± 1.08
−19.85 to
−13.81
<0.001

–
0.43 ± 0.46
−0.86 to 1.73
1.000
−1.99* ± 0.50
−3.38 to −0.60
0.001
−1.59* ± 0.43
−2.78 to −0.39
0.002
−4.012* ± 0.74
−6.10 to −1.93
<0.001

–
−1.53* ± 0.23
−2.17 to −0.88
<0.001
−2.28* ± 0.25
−2.97 to −1.59
<0.001
−1.10* ± 0.21
−1.69 to −0.50
<0.001
−2.01* ± 0.37
−3.04 to −0.98
<0.001

D. MoCA subscore for visuospatial executive function
Healthy controls
–
Asymptomatic genetic Parkinson's disease
−0.30* ± 0.08
−0.52 to −0.08
0.001
Symptomatic genetic Parkinson's disease
−0.43* ± 0.83
−0.67 to −0.20
<0.001
Sporadic Parkinson's disease
−0.17 ± 0.07
−0.37 to 0.03
0.193
Prodromal
−0.62* ± 0.13
−0.97 to −0.27
<0.001
E. MoCA subscore for delayed recall
Healthy controls
Asymptomatic genetic Parkinson's disease

Symptomatic genetic Parkinson's disease

Sporadic Parkinson's disease

–
−0.85* ± 0.13
−1.21 to −0.48
<0.001
−0.66* ± 0.14
−1.05 to −0.27
<0.001
−0.53* ± 0.12
−0.87 to −0.20
<0.001

Asymptomatic genetic
Parkinson's disease

Symptomatic genetic
Parkinson's disease

Sporadic Parkinson's
disease

Possible prodromal
Parkinson's disease

–

−11.50* ± 0.65
−13.32 to −9.68
<0.001

–

−9.57* ± 0.53
−11.07 to −8.07
<0.001
−15.78* ± 1.03
−18.67 to −12.89
<0.001

1.93* ± 0.60
0.26 to 3.61
0.012
−4.28* ± 1.06
−7.27 to −1.29
0.001

–

−6.21* ± 1.00
−9.01 to −3.41
<0.001

–

–

−2.43* ± 0.45
−3.68 to −1.17
<0.001
−2.02* ± 0.37
−3.05 to −0.99
<0.001
−4.45* ± 0.71
−6.44 to −2.46
<0.001

–

0.41 ± 0.41
−0.75 to 1.56
1.000
−2.02 ± 0.73
−4.08 to 0.03
0.058

–

−2.43* ± 0.69
−4.36 to −0.50
0.004

–

–

−0.75* ± 0.22
−1.38 to −0.13
0.007
0.43 ± 0.18
−0.08 to 0.94
0.187
−0.48 ± 0.35
−1.47 to 0.51
1.000

–

1.18* ± 0.20
0.61 to 1.76
<0.001
0.27 ± 0.36
−0.75 to 1.29
1.000

–

−0.91 ± 0.34
−1.87 to 0.05
0.076

–

–

0.13 ± 0.08
−0.08 to 0.34
0.783
−0.13 ± 0.06
−0.31 to 0.04
0.301
0.32 ± 0.12
−0.01 to 0.66
0.070

–

−0.27* ± 0.07
−0.46 to −0.07
0.001
0.19 ± 0.12
−0.16 to 0.54
1.000

–

0.46* ± 0.12
0.13 to 0.78
<0.001

–

–

0.18 ± 0.13
−0.17 to 0.53
1.000
0.31* ± 0.10
0.03 to 0.60
0.023

–

0.13 ± 0.12
−0.19 to 0.45
1.000

–

(continued on next page)
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Table 2 (continued)
Healthy
controls
Prodromal

F. MoCA subscore for attention
Healthy controls
Asymptomatic genetic Parkinson's disease

Symptomatic genetic Parkinson's disease

Sporadic Parkinson's disease

Prodromal

−0.57 ± 0.21
−1.15 to 0.01
0.057

–
−0.18* ± 0.06
−0.35 to 0.00
0.044
−0.40* ± 0.07
−0.59 to −0.22
<0.001
−0.13 ± 0.06
−0.29 to 0.02
0.178
−0.50* ± 0.10
−0.78 to −0.22
<0.001

Asymptomatic genetic
Parkinson's disease

Symptomatic genetic
Parkinson's disease

Sporadic Parkinson's
disease

Possible prodromal
Parkinson's disease

0.27 ± 0.20
−0.28 to 0.83
1.000

0.09 ± 0.20
−0.49 to 0.66
1.000

−0.04 ± 0.19
−0.58 to 0.50
1.000

–

–

−0.23* ± 0.06
−0.40 to −0.06
0.001
0.04 ± 0.49
−0.10 to 0.18
1.000
−0.33* ± 0.09
−0.59 to −0.06
0.006

–

0.27* ± 0.06
0.12 to 0.42
<0.001
−0.10 ± 0.10
−0.37 to 0.18
1.000

–

−0.37* ± 0.09
−0.62 to −0.11
<0.001

–

For the test indicated, the rows of each cell list the mean difference ± standard error (*P < .05), 95% conﬁdence interval, and P value for the indicated pair of diagnostic
categories. UPSIT: University of Pennsylvania Smell Identiﬁcation Test. HVLT: Hopkins Verbal Learning Test. MoCA: Montreal Cognitive Assessment Test. PPMI-deﬁned diagnostic groups: Asymptomatic genetic-Parkinson's-disease subjects have a mutation, or are a ﬁrst-degree relative of an individual having a mutation, in LRRK2, SNCA, or
GBA; Symptomatic-genetic-Parkinson's-disease subjects have a mutation in LRRK2, SNCA, or GBA; Possible-prodromal-Parkinson's-disease subjects have REM-behavior
sleep disorder and/or hyposmia.

visuospatial and executive function also has signiﬁcant indirect effects.
We infer that the HVLT and Visu-Exec each assess cognitive processes
that are also utilized by the UPSIT, and that impairment in those processes
contribute to lowered olfactory-function-test scores in PD.
Both the UPSIT and HVLT are structured to utilize memory and/or
memory retrieval. The UPSIT requires working and/or short-term memory
processes to retain an odor memory while connecting it to semantic and/or
episodic long-term memory to establish an association with its name. The
HVLT presents auditory cues that must be retained in short-term memory
so they can be repeated back. Efﬁcient recall can be aided by making connections among the words using long-term memory. Scores on both tests
will be inﬂuenced by working and/or short-term memory capacity/processes or memory retrieval. The signiﬁcant indirect effects of HVLT scores
for UPSIT scores on the symptomatic diagnostic categories may arise because the HVLT is a good measure for the use of these cognitive domains
within the UPSIT.
Decision-making is a cognitive process utilized by the UPSIT, HVLT and
Visu-Exec. A participant chooses between odor-choices in the UPSIT, strategies for remembering words (e.g., mnemonic, chunking, or relatedness)
and which words to say aloud in the HVLT, and how to draw lines in a speciﬁc direction, order, and location in the Visu-Exec. Their shared signiﬁcant
indirect effects for UPSIT scores on the symptomatic-genetic-PD diagnostic
category likely result from impairment in potentially overlapping cognitive
domains. We hypothesize that the indirect effects of the HVLT and VisuExec arise because these tests are good measures for decision-making processes also used within the UPSIT.
For the sporadic-PD and possible-prodromal-PD diagnostic categories,
the HVLT has signiﬁcant indirect effects, while the Visu-Exec indirect effects only approach signiﬁcance. For the symptomatic-genetic-PD

of the HVLT on the relationships between the UPSIT and the three symptomatic diagnostic categories and 2) signiﬁcant indirect effects of the
Visu-Exec on the relationships between the UPSIT and the genetic diagnostic categories, with the other symptomatic diagnostic categories approaching signiﬁcance. As found for the SEM model including the HVLT
and MoCA, the HVLT also had stronger indirect effects on the
symptomatic-genetic-PD diagnostic category than the Visu-Exec. Strikingly,
Visu-Exec subscores provide a better explanation for UPSIT scores in the genetic diagnostic categories than do total MoCA scores.
Delayed-Recall subscores have signiﬁcant indirect effects on the relationship between UPSIT scores and the diagnostic categories of
asymptomatic-genetic-PD (b = −0.53, P = .017), symptomatic-geneticPD (b = −0.35, P = .019), and sporadic-PD (b = −0.24, P = .026), but
not possible-prodromal-PD (b = −0.01, P = .995). When incorporated
into a SEM model that also includes HVLT scores, however, the indirect effects of Delayed-Recall subscores lose signiﬁcance, just as we found for total
MoCA scores when they were included in a model with HVLT scores
(Fig. 2C).
4. Discussion
In PD, olfactory dysfunction is a common early manifestation [2–6] and
cognitive dysfunction, speciﬁcally visuospatial and executive dysfunction,
is also common [29,30]. Analysis of PPMI data shows that scores on tests
of verbal learning/memory, global cognition, visuospatial-executive function, and delayed-recall are signiﬁcant predictors of olfactory-functiontest scores. Furthermore, SEM analysis demonstrates that in the symptomatic PPMI diagnostic categories, verbal learning/memory is a better indirect
predictor of olfactory deﬁcits than is global cognition. Furthermore,

Fig. 2. Structural equation models assessing the indirect effects of cognitive measures. Models reveal the magnitude and strength of the indirect effect of cognitive measures
on the relationship between UPSIT and the diagnostic categories, accounting for age and sex as covariates. Since the indirect effects between GENUN and HVLT in each model
were non-signiﬁcant, the associations between GENUN and HVLT were ﬁxed to zero to give the models one degree of freedom. Signiﬁcant and nonsigniﬁcant associations
between study variables are depicted by connecting lines as described in the legend. The three sets of values above the lines between diagnostic categories and UPSIT convey
the magnitude (and strength, as p-value), in order, of their direct association, the indirect association of the HVLT along the arrowed lines from the diagnostic category to
HVLT to UPSIT, and, the indirect association of the second cognitive measure along the arrowed lines from the diagnostic category to that measure to UPSIT. Fit statistics
and the variance (R2) in scores explained by the models are indicated. (A) Model assessing the indirect effects of the HVLT and MoCA. (B) Model assessing the indirect effects
of the HVLT and the visuospatial-executive-functioning subscore of the MoCA. (C) Model assessing the indirect effects of the HVLT and the delayed-memory-recall subscore of
the MoCA. Model statistics: χ2 = model chi-square, CFI = comparative ﬁt index, RMSEA = root mean square error of approximation, SRMR = standard root mean square
residual. PPMI-deﬁned diagnostic categories: HC = healthy controls; GENUN = individuals with asymptomatic genetic (LRRK2, SNCA, or GBA) PD; GENPD = individuals
with symptomatic genetic PD; SPD = individuals with sporadic PD at baseline; PROD (possible prodromal PD) = individuals diagnosed with hyposmia and/or RBD.
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in the sporadic-PD diagnostic category are H&Y I-II; those in the possibleprodromal-PD diagnostic category lack motor symptoms and all may not
develop PD. Alternatively, the signiﬁcant indirect effects of HVLT and
Visu-Exec only for the symptomatic-genetic-PD diagnostic category may reﬂect these tests measuring a convergent cognitive process affecting the

diagnostic category, both the HVLT and Visu-Exec each have signiﬁcant indirect effects on the UPSIT. Differences in signiﬁcance of the Visu-Exec indirect effects for different symptomatic diagnostic categories could reﬂect
disease duration, severity, subtype, and/or genetic status: individuals in
the symptomatic-genetic-PD diagnostic category are H&Y I-III while those
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UPSIT only in that diagnostic category, and/or reﬂect a difference in the underlying neurodegenerative mechanism in genetic forms of PD.
Focused tests of memory and decision-making will be useful to better
understand cognitive mechanisms contributing to perceived olfactory dysfunction. While the HVLT and Visu-Exec were strongly signiﬁcant here,
their effect sizes were relatively small. This may reﬂect the multiple levels
at which olfactory dysfunction can occur. Longitudinal assessment to characterize the time course of impairment in speciﬁc cognitive domains relative to olfactory-function-test scores, and whether the strength of an
indirect effect increases with disease severity and duration will provide insight into the etiology of both olfactory dysfunction and the neurodegenerative process.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.prdoa.2019.07.003.
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